A delay differential model for pandemic influenza with antiviral treatment.
The use of antiviral drugs has been recognized as the primary public health strategy for mitigating the severity of a new influenza pandemic strain. However, the success of this strategy requires the prompt onset of therapy within 48 hours of the appearance of clinical symptoms. This requirement may be captured by a compartmental model that monitors the density of infected individuals in terms of the time elapsed since the onset of symptoms. We show that such a model can be expressed by a system of delay differential equations with both discrete and distributed delays. The model is analyzed to derive the criterion for disease control based on two critical factors: (i) the profile of treatment rate; and (ii) the level of treatment as a function of time lag in commencing therapy. Numerical results are also obtained to illustrate the feasible region of disease control. Our findings show that due to uncertainty in the attack rate of a pandemic strain, initiating therapy immediately upon diagnosis can significantly increase the likelihood of disease control and substantially reduce the required community-level of treatment. This suggests that reliable diagnostic methods for influenza cases should be rapidly implemented within an antiviral treatment strategy.
Alexander
Murray E
ME
Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, R3B 1Y6.
Moghadas
Seyed M
SM
Röst
Gergely
G
Wu
Jianhong
J
D000998:Antiviral Agents / Q000627:therapeutic use*; D001294:Attitude to Health; D003140:Communicable Disease Control / Q000706:statistics & numerical data*; D019468:Disease Management; D004196:Disease Outbreaks / Q000706:statistics & numerical data; D018562:Disease Transmission, Infectious / Q000517:prevention & control / Q000706:statistics & numerical data; D042241:Early Diagnosis; D006801:Humans; D015994:Incidence; D007251:Influenza, Human / Q000453:epidemiology* / Q000628:therapy*; D016015:Logistic Models; D009975:Orthomyxoviridae / Q000472:pathogenicity; D010342:Patient Acceptance of Health Care; D013997:Time Factors
D000998:Antiviral Agents
Lancet. 2006 Jan 28;367(9507):303-13
16443037
Am J Epidemiol. 2004 Apr 1;159(7):623-33
15033640
J Infect Dis. 1998 Apr;177(4):863-73
9534957
Emerg Infect Dis. 2006 Jan;12(1):15-22
16494711
Vaccine. 2003 May 1;21(16):1801-3
12686098
J Antimicrob Chemother. 2003 Apr;51(4):977-90
12654752
Nature. 2006 Jul 27;442(7101):448-52
16642006
Nature. 2005 Sep 8;437(7056):209-14
16079797
J Virol. 2006 Aug;80(15):7590-9
16840338
Antiviral Res. 2001 Aug;51(2):81-94
11431034
Proc Biol Sci. 2004 Nov 7;271(1554):2223-32
15539347
Emerg Infect Dis. 2005 Sep;11(9):1355-62
16229762
Emerg Infect Dis. 2006 Jan;12(1):81-7
16494722
Science. 2005 Aug 12;309(5737):1083-7
16079251
J R Soc Interface. 2006 Jun 22;3(8):453-7
16849273
Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40
16585506